Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept.
Elwood
Robert L
RL
Department of Pediatrics, David Grant Medical Center, Travis Air Force Base, CA 94535, USA. Robert.Elwood@60mdg.travis.af.mil
Pelszynski
Mary M
MM
Corman
Larry I
LI
D000900:Anti-Bacterial Agents; D001170:Arthritis, Infectious / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D001171:Arthritis, Juvenile / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D003131:Combined Modality Therapy; D004322:Drainage / Q000379:methods; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D010019:Osteomyelitis / Q000150:complications / Q000209:etiology* / Q000628:therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D018570:Risk Assessment; D013290:Streptococcal Infections / Q000175:diagnosis* / Q000188:drug therapy; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000302:isolation & purification*; D014034:Toes; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept